Trade Cerus Corp - CERS CFD

Cerus Company profile

About Cerus Corporation

Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cerus Corporation revenues increased 40% to $159.5M. Net loss decreased 9% to $54.4M. Revenues reflect United States segment increase of 79% to $96.2M, Other Countries segment increase of 25% to $42.5M. Lower net loss reflects Other Research and development decrease of 4% to $58.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.37 to -$0.32.

Equity composition

Common Stock $.001 Par, 7/11, 112.5M auth., 47,700,000 issd.Insiders control 2.86%. IPO: 2/97, 2M shs. @ $12 by Morgan Stanley & Co. *3/06, PO 4.5M shares + over-allotment 675K shares by Robert W. Baird & Co. Preferred Ser.B $0.001 Par, 5M auth., 3,327 issd shs.